GSK Unveils Promising Results for B7 Drug Data
GSK plc has announced significant progress in its clinical research with mocertatug rezetecan (Mo-Rez), an innovative antibody-drug conjugate. The drug targets the B7-H4 antigen and has shown promising results in the BEHOLD-1 global phase I clinical trial.
Key Findings from the BEHOLD-1 Study
The BEHOLD-1 trial focused on patients with platinum-resistant ovarian cancer (PROC) and recurrent or advanced endometrial cancer (EC). At the highest dosages tested, Mo-Rez achieved:
- 62% confirmed objective response rate (cORR) in PROC.
- 67% cORR in recurrent or advanced EC.
The study demonstrated these results at doses of 5.8 mg/kg for PROC (21 of 34 patients responding, 95% confidence interval: 44-78) and 4.8 mg/kg for EC (8 of 12 patients responding, 95% confidence interval: 35-90).
Clinical Implications
These findings hold particular relevance given the limited treatment options currently available for these cancer types. The B7-H4 antigen is largely expressed in gynecological cancers, offering a targeted approach with potential precision therapy benefits.
As a result of these positive outcomes, GSK plans to initiate five pivotal phase III clinical trials starting in 2026. These trials will further investigate Mo-Rez’s effectiveness in both PROC and endometrial cancers, including evaluations in earlier treatment lines.
Safety and Tolerability Observations
The trial also monitored safety measures. At high doses, treatment-related adverse events (TRAE) led to:
- 0% discontinuation rate in PROC patients due to TRAE.
- 4% discontinuation rate in EC patients due to TRAE.
Nausea was the most frequently reported TRAE, affecting 82% of PROC patients and 75% of EC patients. The incidence of serious grade ≥3 TRAEs was observed in 64% of PROC patients and 54% of EC patients, primarily related to hematologic issues.
Future of Mo-Rez in Cancer Treatment
The BEHOLD clinical program, which includes the BEHOLD-1 and an ongoing BEHOLD-2 combination study, demonstrates GSK’s commitment to developing new therapies for challenging cancers. The planned phase III trials will aim to assess Mo-Rez in broader contexts, including:
- Platinum-sensitive ovarian cancer.
- First-line maintenance in ovarian cancer.
- Mismatch-repair proficient endometrial cancer.
As GSK advances with its global development plan, it continues to focus on enhancing treatment options for patients with gynecologic malignancies.
About GSK
GSK is a leading biopharmaceutical company devoted to the innovation of healthcare solutions. With a focus on advancing oncology and other significant health issues, GSK aims to improve patient outcomes worldwide.
For more updates on GSK’s developments in oncology and other areas, visit Filmogaz.com.